Global assays of fibrinolysis

International Journal of Laboratory Hematology

Volumn 39, Issue 5, 2017, Pages 441-447

  Ilich, A ^a,b   Bokarev, I ^b   Key, N S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

coagulation; euglobulin fraction; fibrinolysis; global assay; thromboelastography; turbidity assay

Indexed keywords

PLASMA PROTEIN FRACTION; PLASMIN; THROMBIN;

ASSAY; BLOOD; EUGLOBULIN LYSIS TEST; FIBRIN PLATE METHOD; FIBRINOLYSIS; GLOBAL FIBRINOLYTIC CAPACITY; GOLD STANDARD; HUMAN; PLASMA; PRIORITY JOURNAL; REVIEW; SIMULTANEOUS THROMBIN AND PLASMIN GENERATION ASSAY; THROMBOELASTOGRAPH; THROMBOELASTOGRAPHY; TURBIDITY; BIOSYNTHESIS; BLOOD CLOTTING; BLOOD CLOTTING TEST; HEMOSTASIS; PROCEDURES; REFERENCE VALUE; STANDARDS;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; FIBRIN CLOT LYSIS TIME; FIBRINOLYSIN; FIBRINOLYSIS; HEMOSTASIS; HUMANS; REFERENCE VALUES; THROMBELASTOGRAPHY; THROMBIN;

EID: 85019060686     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12688     Document Type: Review

References (64)

1. Liu Y, Wang Z, Jiang M, et al. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res. 2011;35:879-884.
2. Hajjar KA, Krishnan S. Annexin II: a mediator of the plasmin/plasminogen activator system. Trends Cardiovasc Med. 1999;9:128-138.
3. Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015;29:17-24.
4. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005;129:307-321.
5. Moir E, Booth NA, Bennett B, Robbie LA. Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u-PA-dependent mechanism. Br J Haematol. 2001;113:72-80.
6. Colman RW. Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun. 1969;35:273-279.
7. Goldsmith GH Jr, Saito H, Ratnoff OS. The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragments. J Clin Investig. 1978;62:54-60.
8. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation. 2000;102:2190-2196.
9. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol. 1988;70:327-333.
10. Falanga A, Russo L, Tartari CJ. Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia. Mediterr J Hematol Infect Dis. 2011;3:e2011068.
11. Carroll VA, Binder BR. The role of the plasminogen activation system in cancer. Semin Thromb Hemost. 1999;25:183-197.
12. Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. Haemophilia. 2008;14:1255-1260.
13. Hjorleifsson E, Sigurdsson MI, Gudmundsdottir BR, Sigurdsson GH, Onundarson PT. Prediction of survival in patients suspected of disseminated intravascular coagulation. Acta Anaesthesiol Scand. 2015;59:870-880.
14. Wohner N, Sotonyi P, Machovich R, et al. Lytic resistance of fibrin containing red blood cells. Arterioscler Thromb Vasc Biol. 2011;31:2306-2313.
15. Averett RD, Norton DG, Fan NK, Platt MO. Computational imaging analysis of fibrin matrices with the inclusion of erythrocytes from homozygous SS blood reveals agglomerated and amorphous structures. J Thromb Thrombolysis. 2017;43:43-51.
16. Hoki S, Suzuki Y, Umemura K, Urano T. Enhancement of fibrinolysis by gel-filtered platelets and its quenching by cytochalasin B and GPIIb/IIIa antagonists. Pharmacol Rep. 2009;61:877-884.
17. Mitchell JL, Mutch NJ. Novel aspects of platelet factor XIII function. Thromb Res. 2016;141(Suppl 2):S17-S21.
18. Carrieri C, Galasso R, Semeraro F, Ammollo CT, Semeraro N, Colucci M. The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood. J Thromb Haemost. 2011;9:154-162.
19. Mitchell JL, Lionikiene AS, Georgiev G, et al. Polyphosphate co-localizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity. Blood. 2016;128:2834-2845.
20. MacLeod TJ, Kwon M, Filipenko NR, Waisman DM. Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem. 2003;278:25577-25584.
21. Miles LA, Ellis V. Alpha-enolase comes muscling in on plasminogen activation. Thromb Haemost. 2003;90:564-566.
22. Das R, Plow EF. Phosphatidylserine as an anchor for plasminogen and its plasminogen receptor, histone H2B, to the macrophage surface. J Thromb Haemost. 2011;9:339-349.
23. Kolev K, Lerant I, Tenekejiev K, Machovich R. Regulation of fibrinolytic activity of neutrophil leukocyte elastase, plasmin, and miniplasmin by plasma protease inhibitors. J Biol Chem. 1994;269:17030-17034.
24. Brower MS, Harpel PC. Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem. 1982;257:9849-9854.
25. Wu K, Urano T, Ihara H, et al. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis. Blood. 1995;86:1056-1061.
26. Ives C, Inaba K, Branco BC, et al. Hyperfibrinolysis elicited via thromboelastography predicts mortality in trauma. J Am Coll Surg. 2012;215:496-502.
27. Schochl H, Frietsch T, Pavelka M, Jambor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma. 2009;67:125-131.
28. Lang T, Bauters A, Braun SL, et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis. 2005;16:301-310.
29. Levrat A, Gros A, Rugeri L, et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth. 2008;100:792-797.
30. Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377:1096-1101, 101.e1-2.
31. Brenner T, Schmidt K, Delang M, et al. Viscoelastic and aggregometric point-of-care testing in patients with septic shock - cross-links between inflammation and haemostasis. Acta Anaesthesiol Scand. 2012;56:1277-1290.
32. Nielsen VG. Hemodilution modulates the time of onset and rate of fibrinolysis in human and rabbit plasma. J Heart Lung Transplant. 2006;25:1344-1352.
33. Diamandis M, Adam F, Kahr WH, et al. Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. J Thromb Haemost. 2006;4:1086-1094.
34. Chitlur M, Sorensen B, Rivard GE, et al. Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia. 2011;17:532-537.
35. Rijken DC, Nobel EHD, Jie AFH, Atsma DE, Schalij MJ, Nieuwenhuizen W. Development of a new test for the global fibrinolytic capacity in whole blood. J Thromb Haemost. 2008;6:151-157.
36. Pieters M, Vorster HH, Jerling JC, et al. The effect of ethanol and its metabolism on fibrinolysis. Thromb Haemost. 2010;104:724-733.
37. Rijken DC, Kock EL, Guimaraes AH, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost. 2012;10:2116-2122.
38. He S, Bremme K, Blomback M. A laboratory method for determination of overall haemostatic potential in plasma I. Method design and preliminary results. Thromb Res. 1999;96:145-156.
39. Antovic JP, Antovic A, He S, Tengborn L, Blomback M. Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII. Haemophilia. 2002;8:781-786.
40. Goldenberg NA, Hathaway WE, Jacobson L, Manco-Johnson MJ. A new global assay of coagulation and fibrinolysis. Thromb Res. 2005;116:345-356.
41. Rooth E, Wallen H, Antovic A, et al. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul Fibrinolysis. 2007;18:365-370.
42. Antovic JP, Yngen M, Ostenson CG, et al. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications. Blood Coagul Fibrinolysis. 2003;14:551-556.
43. Antovic A, Vikerfors A, Woodhams B, Adam M, Svenungsson E. Increased levels of thrombin activatable fibrinolysis inhibitor - tafi correlate with complement activation in patients with the antiphospholipid syndrome. Ann Rheum Dis 2014;73:591.
44. Antovic A. Screening haemostasis–looking for global assays: the Overall Haemostasis Potential (OHP) method–a possible tool for laboratory investigation of global haemostasis in both hypo- and hypercoagulable conditions. Curr Vasc Pharmacol. 2008;6:173-185.
45. Simpson ML, Goldenberg NA, Jacobson LJ, Bombardier CG, Hathaway WE, Manco-Johnson MJ. Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults. Thromb Res. 2011;127:317-323.
46. van Geffen M, Loof A, Lap P, et al. A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis. Hematology. 2011;16:327-336.
47. Amiral J, Pannell R, Lefrancois-Plassart V, Gurewich V. Assay for global fibrinolytic capacity on plasma. Abstract. 11th International Congress on Fibrinolysis Copenhagen, Denmark, June 29-July 3; 1992. 1992.
48. Kockar C, Kockar O, Ozturk M, Dagli M, Bavbek N, Kosar A. Global fibrinolytic capacity increased exponentially in metastatic colorectal cancer. Clin Appl Thromb Hemost. 2005;11:227-230.
49. Peker E, Akbayram S, Geylani H, Dogan M, Kirimi E. Global fibrinolytic capacity in neonatal sepsis. Clin Appl Thromb Hemost. 2011;17:E64-E69.
50. Harmanci A, Kandemir N, Dagdelen S, et al. Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state. J Diabetes Complications. 2006;20:40-44.
51. Guldiken S, Turgut B, Demir M, et al. The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus. Clin Appl Thromb Hemost. 2006;12:55-60.
52. Guldiken S, Demir M, Turgut B, Altun BU, Arikan E, Kara M. Global fibrinolytic capacity in patients with subclinical hypothyroidism. Endocr J. 2005;52:363-367.
53. Yurdakok M, Korkmaz A, Kirazli S, Aygun C, Yigit S. Global fibrinolytic capacity in early respiratory distress syndrome: a pilot study. Am J Hematol. 2002;69:255-257.
54. Atalar E, Ozmen F, Haznedaroglu I, et al. Impaired fibrinolytic capacity in rheumatic mitral stenosis with or without atrial fibrillation and nonrheumatic atrial fibrillation. Int J Hematol. 2002;76:192-195.
55. Aytac S, Turkay C, Bavbek N, Kosar A. Hemostasis and global fibrinolytic capacity in chronic liver disease. Blood Coagul Fibrinolysis. 2007;18:623-626.
56. Fuld E, Spiro K. Ueber die labende und labhemmende Wirkung des Blutes. Hoppe-Seyler′s Z Physiol Chem. 1901;00:132.
57. Milstone H. A Factor in Normal Human Blood which Participates in Streptococcal Fibrinolysis. J Immunol. 1941;42:109-116.
58. Christensen LR, Macleod CM. A proteolytic enzyme of serum: characterization, activation, and reaction with inhibitors. J Gen Physiol. 1945;28:559-583.
59. Urano T, Nishikawa T, Nagai N, Takada Y, Takada A. Amounts of tPA and PAI-1 in the euglobulin fraction obtained at different pH: their relation to the euglobulin clot lysis time. Thromb Res. 1997;88:75-80.
60. Kowarzyk H, Buluk K. Progress of the studies on blood coagulation. Postepy Hig Med Dosw. 1950;2:1-76.
61. Miles LA, Greengard JS, Griffin JH. A comparison of the abilities of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen. Thromb Res. 1983;29:407-417.
62. Tomczyk M, Suzuki Y, Sano H, Brzoska T, Tanaka H, Urano T. Bidirectional functions of thrombin on fibrinolysis: evidence of thrombin-dependent enhancement of fibrinolysis provided by spontaneous plasma clot lysis. Thromb Res. 2016;143:28-33.
63. Astrup T, Mullertz S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys. 1952;40:346-351.
64. Lassen M. Heat denaturation of plasminogen in the fibrin plate method. Acta Physiol Scand. 1953;27:371-376.